BRPI0810522A2 - Mimétricos diazo bicíclicos de smac e uso dos mesmos. - Google Patents

Mimétricos diazo bicíclicos de smac e uso dos mesmos.

Info

Publication number: BRPI0810522A2
Authority: BR; Brazil
Prior art keywords: mimetrics; smac; diazo; bicyclic; same
Prior art date: 2007-04-13

Application number

BRPI0810522-7A2A

Other languages

English (en)

Inventor

Shaomeng Wang

Yuefeng Peng

Haiying Sun

Qian Cai

Zaneta Nikolovska-Coleska

Jianfeng Lu

Su Qiu

Original Assignee

Univ Michigan

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-13

Filing date

2008-04-14

Publication date

2014-10-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39864640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0810522(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-04-14 Application filed by Univ Michigan filed Critical Univ Michigan

2014-10-21 Publication of BRPI0810522A2 publication Critical patent/BRPI0810522A2/pt

2020-02-04 Publication of BRPI0810522B1 publication Critical patent/BRPI0810522B1/pt

2021-05-25 Publication of BRPI0810522B8 publication Critical patent/BRPI0810522B8/pt

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Epidemiology (AREA)

BRPI0810522A 2007-04-13 2008-04-14 compostos miméticos diazo bicíclicos de smac, composição farmacêutica e kit compreendendo ditos compostos e uso dos mesmos para o tratamento de câncer BRPI0810522B8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US92334807P	2007-04-13	2007-04-13
PCT/US2008/060215 WO2008128171A2 (en)	2007-04-13	2008-04-14	Diazo bicyclic smac mimetics and the uses thereof

Publications (3)

Publication Number	Publication Date
BRPI0810522A2 true BRPI0810522A2 (pt)	2014-10-21
BRPI0810522B1 BRPI0810522B1 (pt)	2020-02-04
BRPI0810522B8 BRPI0810522B8 (pt)	2021-05-25

Family

ID=39864640

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0810522A BRPI0810522B8 (pt)	2007-04-13	2008-04-14	compostos miméticos diazo bicíclicos de smac, composição farmacêutica e kit compreendendo ditos compostos e uso dos mesmos para o tratamento de câncer

Country Status (22)

Country	Link
US (2)	US8278293B2 (pt)
EP (1)	EP2139490B1 (pt)
JP (1)	JP5416089B2 (pt)
KR (1)	KR101081685B1 (pt)
CN (1)	CN101686981B (pt)
AU (1)	AU2008240119B2 (pt)
BR (1)	BRPI0810522B8 (pt)
CA (1)	CA2683318C (pt)
CY (1)	CY1115735T1 (pt)
DK (1)	DK2139490T3 (pt)
EA (1)	EA017797B1 (pt)
ES (1)	ES2504216T3 (pt)
HR (1)	HRP20140885T1 (pt)
HU (1)	HUE024142T2 (pt)
IL (1)	IL201474A (pt)
MX (1)	MX2009011069A (pt)
NZ (1)	NZ580468A (pt)
PL (1)	PL2139490T3 (pt)
PT (1)	PT2139490E (pt)
SI (1)	SI2139490T1 (pt)
WO (1)	WO2008128171A2 (pt)
ZA (1)	ZA200907055B (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4954983B2 (ja)	2005-05-18	2012-06-20	ファーマサイエンス・インコーポレイテッド	Ｂｉｒドメイン結合化合物
JP2009512719A (ja)	2005-10-25	2009-03-26	アエゲラセラピューティクスインコーポレイテッド	Ｉａｐｂｉｒドメイン結合化合物
TWI504597B (zh)	2006-03-16	2015-10-21	Pharmascience Inc	結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
PL2139490T3 (pl) *	2007-04-13	2014-11-28	Univ Michigan Regents	Diazobicykliczne mimetyki Smac i ich zastosowania
US8815927B2 (en)	2009-10-23	2014-08-26	The Regents Of The University Of Michigan	Bivalent diazo bicyclic Smac mimetics and the uses thereof
CN102666588A (zh) *	2009-11-05	2012-09-12	Uab研究基金会	治疗基底细胞样基因型癌症
MX340870B (es)	2010-02-12	2016-07-27	Pharmascience Inc	Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
WO2012052758A1 (en)	2010-10-22	2012-04-26	Astrazeneca Ab	Response biomarkers for iap antagonists in human cancers
GB201106817D0 (en) *	2011-04-21	2011-06-01	Astex Therapeutics Ltd	New compound
KR102237888B1 (ko) *	2012-08-23	2021-04-07	더 리젠츠 오브 더 유니버시티 오브 미시간	Iap 단백질의 2가 억제제 및 그를 사용하는 치료 방법
JP6382831B2 (ja)	2012-11-30	2018-08-29	サンフォード−バーンハムメディカルリサーチインスティテュート	アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
BR112016002613A2 (pt)	2013-09-09	2017-08-01	Halliburton Energy Services Inc	método de cimentação, composição de cimento de pega lenta e sistema para a cimentação
CA2974651A1 (en)	2014-01-24	2015-07-30	Children's Hospital Of Eastern Ontario Research Institute Inc.	Smc combination therapy for the treatment of cancer
US20180228907A1 (en)	2014-04-14	2018-08-16	Arvinas, Inc.	Cereblon ligands and bifunctional compounds comprising the same
EP3151920A4 (en) *	2014-06-04	2017-12-27	Sanford-Burnham Medical Research Institute	Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
WO2016079527A1 (en)	2014-11-19	2016-05-26	Tetralogic Birinapant Uk Ltd	Combination therapy
WO2016097773A1 (en)	2014-12-19	2016-06-23	Children's Cancer Institute	Therapeutic iap antagonists for treating proliferative disorders
US12312316B2 (en)	2015-01-20	2025-05-27	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of androgen receptor
EP3247708A4 (en)	2015-01-20	2018-09-12	Arvinas, Inc.	Compounds and methods for the targeted degradation of the androgen receptor
GB201506871D0 (en)	2015-04-22	2015-06-03	Glaxosmithkline Ip Dev Ltd	Novel compounds
GB201506872D0 (en) *	2015-04-22	2015-06-03	Ge Oil & Gas Uk Ltd	Novel compounds
US20180147202A1 (en)	2015-06-05	2018-05-31	Arvinas, Inc.	TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
US10772962B2 (en)	2015-08-19	2020-09-15	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of bromodomain-containing proteins
JP2019514878A (ja)	2016-04-20	2019-06-06	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	Ｒｉｐｋ２阻害剤を含むコンジュゲート
GB201610147D0 (en)	2016-06-10	2016-07-27	Glaxosmithkline Ip Dev Ltd	Novel compounds
IL290809B2 (en)	2016-11-01	2024-01-01	Arvinas Operations Inc	PROTACS Targeted Tau-Protein and Related Methods of Use
HUE064609T2 (hu)	2016-12-01	2024-04-28	Arvinas Operations Inc	Tetrahidronaftalin és tetrahidroizokinolin származékok mint ösztrogénreceptor-lebontó anyagok
CN110753693A (zh)	2016-12-23	2020-02-04	阿尔维纳斯运营股份有限公司	Egfr蛋白水解靶向嵌合分子和相关使用方法
EP3558994A4 (en)	2016-12-23	2021-05-12	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US10806737B2 (en)	2016-12-23	2020-10-20	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11173211B2 (en)	2016-12-23	2021-11-16	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11191741B2 (en)	2016-12-24	2021-12-07	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
KR20230140606A (ko)	2017-01-26	2023-10-06	아비나스 오퍼레이션스, 인코포레이티드	에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
US20210198365A1 (en)	2017-10-19	2021-07-01	Merck Patent Gmbh	Combination product for the treatment of cancer
US11065231B2 (en)	2017-11-17	2021-07-20	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
US11028088B2 (en)	2018-03-10	2021-06-08	Yale University	Modulators of BTK proteolysis and methods of use
AU2019249231B2 (en)	2018-04-04	2022-04-21	Arvinas Operations, Inc.	Modulators of proteolysis and associated methods of use
US20200038513A1 (en)	2018-07-26	2020-02-06	Arvinas Operations, Inc.	Modulators of fak proteolysis and associated methods of use
JP7515175B2 (ja)	2018-07-31	2024-07-12	ファイメクス株式会社	複素環化合物
CN112912376A (zh)	2018-08-20	2021-06-04	阿尔维纳斯运营股份有限公司	用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
MX2021002559A (es)	2018-09-07	2021-07-21	Arvinas Operations Inc	Compuestos policiclicos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma rapidamente acelerado.
WO2020109328A1 (en)	2018-11-26	2020-06-04	Debiopharm International S.A.	Combination treatment of hiv infections
US10870663B2 (en)	2018-11-30	2020-12-22	Glaxosmithkline Intellectual Property Development Limited	Compounds useful in HIV therapy
US20220096436A1 (en)	2019-01-17	2022-03-31	Debiopharm International S.A.	Combination product for the treatment of cancer
CA3130706A1 (en)	2019-04-04	2020-10-08	Dana-Farber Cancer Institute, Inc.	Cdk2/5 degraders and uses thereof
CN110028508B (zh) *	2019-05-16	2021-05-28	南京华威医药科技集团有限公司	一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂
CN114867727B (zh)	2019-07-17	2025-02-21	阿尔维纳斯运营股份有限公司	Tau蛋白靶向化合物及相关使用方法
US20220402935A1 (en)	2019-07-31	2022-12-22	Fimecs, Inc.	Heterocyclic compound
BR112022003490A2 (pt)	2019-08-26	2022-05-24	Arvinas Operations Inc	Método de tratamento do câncer de mama e mama metastático, método para degradação seletiva, método para inibir uma quinase, kit, composição líquida, e, método de produção de uma composição líquida
WO2021058794A1 (en)	2019-09-25	2021-04-01	Debiopharm International S.A.	Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
EP4093394A1 (en) *	2020-01-20	2022-11-30	Astrazeneca AB	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US12180193B2 (en)	2020-08-28	2024-12-31	Arvinas Operations, Inc.	Accelerating fibrosarcoma protein degrading compounds and associated methods of use
TW202214236A (zh)	2020-09-14	2022-04-16	美商亞文納營運公司	用於靶向降解雌激素受體之化合物之結晶及非晶形形式
WO2024022275A1 (zh)	2022-07-29	2024-02-01	苏州科睿思制药有限公司	Xevinapant的晶型及其制备方法和用途
WO2024054591A1 (en)	2022-09-07	2024-03-14	Arvinas Operations, Inc.	Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
CN118027138A (zh) *	2022-11-07	2024-05-14	南京中澳转化医学研究院有限公司	吡啶酮类化合物及其制备方法、药物组合物和应用
AR131299A1 (es) *	2022-12-09	2025-03-05	Debiopharm Int Sa	Nuevos inhibidores de iap, métodos para fabricarlos y usos de los mismos
WO2024240858A1 (en)	2023-05-23	2024-11-28	Valerio Therapeutics	Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3989816A (en)	1975-06-19	1976-11-02	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en)	1980-04-04	1984-04-24	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacyclopentan-2-ones
WO2003013571A1 (en)	2001-08-10	2003-02-20	Palatin Technologies, Inc.	Peptidomimetics of biologically active metallopeptides
EP1718300A4 (en) *	2004-01-16	2008-05-14	Univ Michigan	CONFORMATIVELY IMPROVED SMAC MIMETIKA AND ITS USES
WO2006010118A2 (en)	2004-07-09	2006-01-26	The Regents Of The University Of Michigan	Conformationally constrained smac mimetics and the uses thereof
WO2006010119A2 (en)	2004-07-09	2006-01-26	Michael Norris	Cargo retaining device for use in vehicle cargo storage areas
EA017279B1 (ru) *	2006-05-05	2012-11-30	Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган	БИВАЛЕНТНЫЕ МИМЕТИКИ Smac И ИХ ПРИМЕНЕНИЯ
US8202902B2 (en) *	2006-05-05	2012-06-19	The Regents Of The University Of Michigan	Bivalent SMAC mimetics and the uses thereof
PL2139490T3 (pl) *	2007-04-13	2014-11-28	Univ Michigan Regents	Diazobicykliczne mimetyki Smac i ich zastosowania
US8445473B2 (en) *	2008-04-11	2013-05-21	The Regents Of The University Of Michigan	Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof
US8625740B2 (en) *	2011-04-14	2014-01-07	Morpho Detection, Inc.	System and method for correcting X-ray diffraction profiles

2008
- 2008-04-14 PL PL08745750T patent/PL2139490T3/pl unknown
- 2008-04-14 BR BRPI0810522A patent/BRPI0810522B8/pt active IP Right Grant
- 2008-04-14 HU HUE08745750A patent/HUE024142T2/en unknown
- 2008-04-14 US US12/159,249 patent/US8278293B2/en active Active
- 2008-04-14 SI SI200831285T patent/SI2139490T1/sl unknown
- 2008-04-14 AU AU2008240119A patent/AU2008240119B2/en active Active
- 2008-04-14 NZ NZ580468A patent/NZ580468A/en unknown
- 2008-04-14 WO PCT/US2008/060215 patent/WO2008128171A2/en active Application Filing
- 2008-04-14 CN CN2008800186484A patent/CN101686981B/zh active Active
- 2008-04-14 CA CA2683318A patent/CA2683318C/en active Active
- 2008-04-14 MX MX2009011069A patent/MX2009011069A/es active IP Right Grant
- 2008-04-14 ES ES08745750.3T patent/ES2504216T3/es active Active
- 2008-04-14 DK DK08745750.3T patent/DK2139490T3/da active
- 2008-04-14 PT PT87457503T patent/PT2139490E/pt unknown
- 2008-04-14 EP EP08745750.3A patent/EP2139490B1/en active Active
- 2008-04-14 HR HRP20140885AT patent/HRP20140885T1/hr unknown
- 2008-04-14 EA EA200901400A patent/EA017797B1/ru unknown
- 2008-04-14 KR KR1020097023384A patent/KR101081685B1/ko active Active
- 2008-04-14 JP JP2010503269A patent/JP5416089B2/ja active Active
2009
- 2009-10-09 ZA ZA2009/07055A patent/ZA200907055B/en unknown
- 2009-10-12 IL IL201474A patent/IL201474A/en active IP Right Grant
2012
- 2012-07-25 US US13/557,804 patent/US8664212B2/en active Active
2014
- 2014-09-29 CY CY20141100792T patent/CY1115735T1/el unknown

Also Published As

Publication number	Publication date
EP2139490A2 (en)	2010-01-06
EA017797B1 (ru)	2013-03-29
PT2139490E (pt)	2014-10-08
NZ580468A (en)	2012-02-24
BRPI0810522B8 (pt)	2021-05-25
EA200901400A1 (ru)	2010-04-30
JP2010523722A (ja)	2010-07-15
KR20100005213A (ko)	2010-01-14
HUE024142T2 (en)	2016-02-29
US20100273812A1 (en)	2010-10-28
DK2139490T3 (da)	2014-09-08
WO2008128171A2 (en)	2008-10-23
WO2008128171A3 (en)	2008-12-11
CA2683318A1 (en)	2008-10-23
AU2008240119A1 (en)	2008-10-23
HK1141456A1 (en)	2010-11-12
EP2139490A4 (en)	2010-10-27
CY1115735T1 (el)	2017-01-25
CN101686981A (zh)	2010-03-31
HRP20140885T1 (hr)	2014-11-21
JP5416089B2 (ja)	2014-02-12
MX2009011069A (es)	2009-12-03
ES2504216T3 (es)	2014-10-08
US8278293B2 (en)	2012-10-02
CA2683318C (en)	2012-10-30
PL2139490T3 (pl)	2014-11-28
AU2008240119B2 (en)	2012-04-05
EP2139490B1 (en)	2014-07-02
KR101081685B1 (ko)	2011-11-09
ZA200907055B (en)	2011-03-30
CN101686981B (zh)	2013-04-10
US20120309961A1 (en)	2012-12-06
BRPI0810522B1 (pt)	2020-02-04
IL201474A0 (en)	2010-05-31
US8664212B2 (en)	2014-03-04
SI2139490T1 (sl)	2014-11-28
IL201474A (en)	2015-11-30

Publication	Publication Date	Title
BRPI0810522A2 (pt)	2014-10-21	Mimétricos diazo bicíclicos de smac e uso dos mesmos.
CR10743A (es)	2009-06-05	Derivados de azaadamantano y metodos de uso de los mismos
BRPI0808013A2 (pt)	2014-06-17	Compostos de quinoxalina e uso dos mesmos
ES2355534T8 (es)	2011-05-09	Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina.
CR10847A (es)	2009-07-13	Compuesto heteromonociclico y uso del mismo
CR10709A (es)	2009-07-14	Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
BRPI0811635A2 (pt)	2014-11-11	Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0821668A2 (pt)	2015-06-16	Uso
BRPI0815811A2 (pt)	2015-02-18	Derivados de indol substituído e métodos de uso dos mesmos
HRP20161230T1 (hr)	2016-11-18	Aerosolizirani fluorokinoloni i njihova uporaba
DOP2010000260A (es)	2010-10-15	Derivado heterociclico fusionado y su uso
BRPI0720625A2 (pt)	2014-03-25	Derivados de indol de 4,5-anel anulados e métodos de uso dos mesmos
BRPI0815588A2 (pt)	2015-02-18	Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano
MX301032B (es)	2012-07-06	Acetales de levuminato de glicerol y su uso
CR10725A (es)	2009-05-12	Compuestos de pirazolina y su uso y composiones farmaceuticas
DE602006020394D1 (de)	2011-04-14	Objektdetektion
SMT201500218B (it)	2015-10-30	Composti aril-fenil-solfonammido-cicloalchile e loro uso
BRPI0813457A2 (pt)	2014-12-23	Composto de organoenxofre contendo halogênio e uso do mesmo
BRPI0812909A2 (pt)	2014-12-09	Derivados de guanina policíclica e métodos de uso dos mesmos.
BRPI1010024A2 (pt)	2019-09-24	derivados de aminopirrolidinona e uso dos mesmos
DK2079485T3 (da)	2012-08-06	Phenylpropionamidforbindelser og anvendelsen deraf
BRPI0717411A2 (pt)	2013-11-12	Uso de inibidores de iap
EP1896395A4 (en)	2010-12-01	MODIFIED DERIVATIVES OF MALONATE
DK1957492T3 (da)	2011-02-28	Substituerede bicykliske pyrimidonderivater
BRPI0815094A2 (pt)	2015-02-03	Ácidos nucleicos de ligação de sdf-1 e o uso dos mesmos.

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-02-12	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-04-02	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-08-20	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-12-31	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-02-04	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/02/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF